EUVIMEDEUVIMED entdecken
Crossref

Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab

Shoaib Ugradar iD, Erin Zimmerman, Emanuil Parunakian, Julia Kang, Kimberly Cockerham, Raymond S Douglas

Clinical & Experimental Ophthalmology · 2023

DOI: 10.1111/ceo.14208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2023. Verfasst von Shoaib Ugradar und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Jules Stein Eye Institute University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Lacrimal Apparatus, Dry Eye Syndromes, Graves Ophthalmopathy, Exophthalmos. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dry eye syndrome occurs in up to 85% of patients with thyroid eye disease (TED). Lacrimal gland enlargement correlates with subjective tearing and a reduction in quality of life in patients with TED.

Methods

In this prospective longitudinal study, patients presenting for the treatment of TED were considered for eligible. Primary outcomes included a change in the volume of the lacrimal gland and the production of tears following treatment with teprotumumab. The volume of lacrimal glands and proptosis was calculated using 3D volumetric analysis. Tear production was measured by Schirmer's test and associated symptoms were assessed using the VLSQ‐8. The orbit with the most proptosis was designated the study orbit and the contralateral orbit was designated the fellow orbit.

Results

Twenty patients were included. Mean (SD) age was 61 (18) and mean duration of TED prior to therapy was 48 months (47). Lacrimal gland volume in the study orbit decreased from 768 mm 3 (288) to 486 mm 3 (173) ( p < 0.01) following therapy. For the fellow orbit, volume reduced from 637 mm 3 (261) to 379 mm 3 (147) ( p < 0.01). Schirmer's test reading (STR) in the study orbit increased from 14.5 mm (8.2) to 23 mm (10) ( p < 0.01) (59%) following treatment. In the fellow orbit, STR increased from 12.7 mm (7) to 21 mm (9) post therapy (69%) ( p < 0.01). There was a significant improvement on all parts of the VLSQ‐8.

Conclusion

Teprotumumab significantly reduces TED related expansion of the lacrimal gland, increases tear production, and improves dry eye symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacrimal ApparatusDry Eye SyndromesGraves OphthalmopathyExophthalmosHumansChild, PreschoolLongitudinal StudiesProspective StudiesQuality of LifeTearsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

eyelidorbitteprotumumabthyroid

Substanzen

teprotumumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • The Jules Stein Eye Institute University of California, Los Angeles, California, USA.
  • Cedars-Sinai Medical Centre, Los Angeles, California, USA.
  • Central Valley Eye Medical Group, Stockton, California, USA.
  • Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA.

ORCID-Profile: Shoaib Ugradar

Zitieren

APA

Ugradar, S., Zimmerman, E., Parunakian, E., Kang, J., Cockerham, K., & Douglas, R. S. (2023). Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14208

Vancouver

Ugradar S, Zimmerman E, Parunakian E, Kang J, Cockerham K, Douglas RS. Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clinical & Experimental Ophthalmology. 2023. doi:10.1111/ceo.14208

BibTeX
@article{Ugradar2023,
  author = {Ugradar, Shoaib and Zimmerman, Erin and Parunakian, Emanuil and Kang, Julia and Cockerham, Kimberly and Douglas, Raymond S},
  title = {Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2023},
  doi = {10.1111/ceo.14208}
}
Kostenlos starten →